Home › Modalities › Radioligand

Radioligand (6 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AKTS Aktis Oncology Oncology 2 Phase 1 $910M 10
DRTS Alpha Tau Medical Oncology 6 Phase 2 $1.12B 6
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $224M 4
CLRB Cellectar Biosciences Oncology 7 Phase 2 $9.2M 7
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
CATX Perspective Therapeutics Oncology 5 Phase 1 $104M 5